Peter Whitfeld

G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia.

Part of GroPrep Ltd., Biotech Australia develops medicines and technologies used for targeting specific diseases. Biotech Australia was acquired by GroPrep Ltd. on February 27, 2002.

Novozymes Biopharma AU Ltd. manufactures pharmaceuticals. The company is headquartered in Thebarton, Australia.

The Fox Chase Cancer Center owns and operates hospitals. It is an independent, non-profit institution that is engaged in cancer treatment, research and prevention services. The firm's staff provides consultations and treatment recommendations for different types of adult cancer. The company was founded in 1904 and is headquartered in Philadelphia, PA.

The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia.